<?xml version="1.0" encoding="UTF-8"?>
<p id="Par23">We model the impact on HCV incidence and chronic prevalence among PLWH and overall until 2030 with the following scenarios: 
 <list list-type="order">
  <list-item>
   <p id="Par24">
    <bold>Status quo:</bold> Continuing current treatment rates (33%/year among diagnosed HIV/HCV coinfected individuals from 2015 as observed in the HERACLES cohort from 2015 to 2017)
   </p>
  </list-item>
  <list-item>
   <p id="Par25">
    <bold>Coinfected scale-up from 2020:</bold> 100% screening and treatment of coinfected individuals
   </p>
  </list-item>
  <list-item>
   <p id="Par26">
    <bold>All PWID scale-up from 2020:</bold> As in [
    <xref ref-type="bibr" rid="CR2">2</xref>] plus HCV treatment of HCV moninfected PWID of 10%/yr
   </p>
  </list-item>
  <list-item>
   <p id="Par27">
    <bold>No scale-up from 2015</bold> (counterfactual scenario of continuation of historic treatment rates of 10.5% among diagnosed HIV/HCV coinfected individuals)
   </p>
  </list-item>
 </list>
</p>
